Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...
Main Authors: | Sun Joo Cha, Kiyoung Kim |
---|---|
פורמט: | Article |
שפה: | English |
יצא לאור: |
MDPI AG
2022-01-01
|
סדרה: | Antioxidants |
נושאים: | |
גישה מקוונת: | https://www.mdpi.com/2076-3921/11/2/195 |
פריטים דומים
-
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
מאת: Erdi Şahin
יצא לאור: (2018-03-01) -
Edaravone: A new hope for patients with amyotrophic lateral sclerosis
מאת: Shivangi Garg, et al.
יצא לאור: (2019-01-01) -
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
מאת: Hideki Houzen, et al.
יצא לאור: (2021-07-01) -
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
מאת: Jin-Mo Park, et al.
יצא לאור: (2022-07-01) -
Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
מאת: Chang Liu, et al.
יצא לאור: (2024-10-01)